Larimar Therapeutics Azioni (NASDAQ: LRMR)

Ultime notizie per Larimar Therapeutics (NASDAQ:LRMR) Azioni

LARIMAR THERAPEUTICS INC

Larimar Therapeutics

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics Inc

Canaccord Genuity Group (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CF#TSX">CF</a>) reported quarterly earnings of $0.12 per share which missed the analyst consensus estimate of $0.17 by 29.41 percent. This is a 20 percent decrease over earnings of $0.15 per share from the same period last year. The company reported quarterly sales of $461.23 million which missed the analyst consensus estimate of $466.95 million by 1.23 percent. This is a 12.76 percent increase over sales of $409.05 million the same period last year.

Earnings

Earnings Misses

News

TSX:CF

Canaccord Genuity Group Q4 Adj. EPS $0.12 Misses $0.17 Estimate, Sales $461.23M Miss $466.95M Estimate

<a href="https://www.reuters.com/sustainability/boards-policy-regulation/doordash-grubhub-uber-eats-settle-with-new-york-city-over-fee-caps-2025-06-04/">https://www.reuters.com/sustainability/boards-policy-regulation/doordash-grubhub-uber-eats-settle-with-new-york-city-over-fee-caps-2025-06-04/</a>

General

DASH

UBER

'DoorDash, Grubhub, Uber Eats settle with New York City over fee caps'- Reuters

In the current session, the stock is trading at $687.33, after a 3.07% increase. Over the past month, Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) stock increased by 15.27%, and in the past year, by 39.33%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1749074431_0.png" alt="Past Year Chart" />

<h3>Comparing Meta Platforms P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Meta Platforms has a lower P/E than the aggregate P/E of 34.6 of the Interactive Media &amp; Services industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1749074431_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

A Look Into Meta Platforms Inc's Price Over Earnings

Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) has outperformed the market over the past 5 years by 7.9% on an annualized basis producing an average annual return of 21.09%. Currently, Caterpillar has a market capitalization of $164.11 billion. 
Buying $100 In CAT: If an investor had bought $100 of CAT stock 5 years ago, it would be worth $253.65 today based on a price of $348.93 for CAT at the time of writing.
<h3>Caterpillar's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749074414_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $100 Invested In Caterpillar 5 Years Ago Would Be Worth Today

A movie about the <a href="https://www.benzinga.com/news/23/12/36171063/what-really-happened-with-sam-altman-getting-fired-as-openai-ceo-new-details-emerge">firing and rehiring</a> of OpenAI co-founder and CEO Sam Altman is in the works.
Here are the early details.
What Happened: Best known as the parent company of ChatGPT, OpenAI has been one of the most talked about AI companies in recent years. The company has also faced a handful of controversies, including <a href="https://www.benzinga.com/25/02/43609104/elon-musk-co-founded-openai-now-hes-bidding-974b-to-take-back-the-company">a legal battle</a> with Elon Musk.
One of the company's controversies is being turned into a movie tentatively titled "Artificial."
The film will center on the firing and rehiring of Altman that happened back in 2023, as <a href="https://www.hollywoodreporter.com/movies/movie-news/luca-guadagnino-to-direct-openai-movie-1236236357/">reported </a>by The Hollywood Reporter.
The film is being produced by Amazon MGM Studios, a unit of Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>). The report did not say if the film would hit movie theaters or be streamed on Prime Video.
Luca Guadagnino, who has been behind films like "Challengers," "Call Me By Your Name" and "Suspiria" is set to direct the true-life film.
Among the actors attached to the film are Andrew Garfield, Monica Barbaro, and Yura Borisov. Garfield, who has played Spider-Man in films, is said to be the frontrunner to portray Altman in the film. Barbaro is in talks to play chief technology officer Mira Murati, and Borisov would play OpenAI co-founder Ilya Sutskever, according to the report.
Read Also:<a href="https://www.benzinga.com/news/23/03/31266515/5-things-you-might-not-know-about-openai-founder-sam-altman-doomsday-prepper-donald-trump-critic-and"> 5 Things You Might Not Know About OpenAI Founder Sam Altman: Doomsday Prepper, Donald Trump Critic And More</a>
What's Next: While no casting decisions have been made, the report said things are moving fast and the movie could go into production this summer.
Altman is best known as the co-founder and CEO of OpenAI. In 2023, the company&#8217;s Board of Directors fired him, with reports that Sutskever led the decision.
The movie would likely center on the reasons why Altman was let go and why he was quickly hired back to lead the company.
Sutskever<a href="https://www.benzinga.com/news/24/05/38834519/openai-chief-scientist-ilya-sutskever-steps-down-ceo-sam-altman-calls-him-a-guiding-light-of-ai-fiel"> stepped down</a> from OpenAI in 2024 and went on to found another AI company called Safe Superintelligence. That company was valued at a reported $30 billion <a href="https://www.benzinga.com/tech/25/02/43772135/ex-openai-chief-scientist-ilya-sutskevers-ai-startup-valued-at-30-billion-in-latest-funding-round-report">earlier this year.</a>
OpenAI <a href="https://www.benzinga.com/25/04/44580172/openai-finalizes-historic-40-billion-funding-round-valuing-company-at-300-billion-with-backing-from-softbank-and-microsoft">is valued at </a>$300 billion with Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) one of the largest investors in the AI company.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45739990/microsoft-brings-openais-sora-to-the-masses-with-free-ai-video-generator-in-bing-app-after-googles-v">Microsoft Brings OpenAI&#8217;s Sora To The Masses With Free AI Video Generator In Bing App After Google&#8217;s Veo 3 Wowed The Internet—Here&#8217;s What You Can (And Can&#8217;t) Do</a></li>
</ul>
Photo: jamesonwu1972/Shutterstock

Entertainment

Tech

AMZN

MSFT

Sam Altman's 2023 OpenAI Ouster Becoming A Movie: Could Former Spider-Man Play Him?

Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) has outperformed the market over the past 5 years by 4.46% on an annualized basis producing an average annual return of 17.65%. Currently, Halozyme Therapeutics has a market capitalization of $6.59 billion. 
Buying $1000 In HALO: If an investor had bought $1000 of HALO stock 5 years ago, it would be worth $2,250.31 today based on a price of $53.51 for HALO at the time of writing.
<h3>Halozyme Therapeutics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749073516_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HALO

Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years

<a href="https://www.bloomberg.com/news/articles/2025-06-04/walmart-pledges-transparency-on-prices-after-drawing-trump-s-ire?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-04/walmart-pledges-transparency-on-prices-after-drawing-trump-s-ire?embedded-checkout=true</a>

'Walmart Pledges Transparency on Prices After Drawing Trump's Ire'- Bloomberg

Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares closed Wednesday up 0.5% at $141.92. The company announced that its Blackwell architecture delivered breakthrough performance in its latest training results.
What To Know: The volatility in Nvidia shares on Wednesday came as the company said in a blog post that its AI platform delivered the highest performance at scale on all benchmarks and powered every result submitted on the benchmark's toughest large language model-focused test. 
Blackwell delivered more than 2x greater performance compared with the company&#8217;s previous-generation architecture. The company said the results underscore the platform&#8217;s exceptional performance and versatility across a wide array of AI workloads. Nvidia presented at the BofA Securities 2025 Global Technology Conference on Wednesday. 
Nvidia made headlines earlier this week by <a href="https://www.benzinga.com/markets/tech/25/06/45763363/nvidia-overtakes-microsoft-as-the-worlds-most-valuable-company-with-3-4-trillion-market-cap-as-morgan-stanley-reaffirms-top-pick-status">overtaking Microsoft </a>to become the world's most valuable company, now valued at approximately $3.44 trillion. The jump in shares follows strong first-quarter earnings in which the company reported $44.1 billion in revenue, representing a 69% year-over-year increase, ahead of Wall Street expectations. 
Analysts at Morgan Stanley maintained Nvidia as a top pick, citing growing demand for its AI chips across data centers and gaming. Several other analysts raised price targets over the past week, ranging from $135 to $210.
Wedbush&#8217;s Dan Ives said earlier this week that Nvidia could <a href="https://www.benzinga.com/markets/equities/25/06/45767936/tech-bull-says-nvda-can-be-a-250-stock-if-trump-takes-a-step-back-from-tariffs">climb to $250</a> per share over the coming years if the Trump administration pulls back on tariffs. He also indicated that new all-time highs are on the horizon for tech stocks. The broader semiconductor sector got a boost on Wednesday after GlobalFoundries announced plans to commit $16 billion towards U.S. chip expansion. The move is part of an industry-wide reshoring trend driven by AI demand and ongoing trade tensions. The expansion includes new investments in silicon photonics, GaN power technologies and advanced packaging, all critical for energy-efficient AI chips.
Nvidia continues to benefit from strong institutional and investor confidence tied to the long-term demand for AI infrastructure.
NVDA Price Action: Nvidia shares are up about 21% over the past month, and the stock has climbed more than 5% over the past week, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/market-summary/25/06/45777558/stocks-stall-on-weak-economic-data-treasuries-eyes-best-rally-in-7-months-whats-driving-markets-wednesday">Stocks Stall On Weak Economic Data, Treasuries Eyes Best Rally In 7 Months: What&#8217;s Driving Markets Wednesday?</a></li>
</ul>
Image via Shutterstock.

Movers

NVDA

What's Going On With Nvidia Stock?

Gran Tierra Energy To Sell Gran Tierra North Sea Limited To NEO Energy For $7.5M

Transcontinental (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TCL#TSX">TCL</a>) reported quarterly earnings of $0.58 per share which beat the analyst consensus estimate of $0.54 by 7.41 percent. This is a 11.54 percent increase over earnings of $0.52 per share from the same period last year. The company reported quarterly sales of $684.10 million which beat the analyst consensus estimate of $662.74 million by 3.22 percent. This is a 0.13 percent increase over sales of $683.20 million the same period last year.

Earnings Beats

TSX:TCL

TSX:TCL.A

Transcontinental Q2 Adj. EPS $0.58 Beats $0.54 Estimate, Sales $684.10M Beat $662.74M Estimate

FOUR

Shift4 Payments Restructuring Transactions Agreement Terminated Due To Unmet Conditions

Monolithic Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) has outperformed the market over the past 15 years by 15.43% on an annualized basis producing an average annual return of 27.41%. Currently, Monolithic Power Systems has a market capitalization of $33.89 billion. 
Buying $100 In MPWR: If an investor had bought $100 of MPWR stock 15 years ago, it would be worth $3,870.47 today based on a price of $694.75 for MPWR at the time of writing.
<h3>Monolithic Power Systems's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749072622_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MPWR

$100 Invested In Monolithic Power Systems 15 Years Ago Would Be Worth This Much Today

Management

Shift4 Payments Jared Isaacman Resigns As Shift4 Payments CEO Effective June 5, 2025; Taylor Lauber Appointed As New Shift4 Payments CEO; Jared Isaacman Appointed Executive Chairman Of Shift4 Payments

<a href="https://www.reuters.com/sustainability/boards-policy-regulation/apple-loses-bid-pause-app-store-reform-order-epic-games-case-2025-06-04/">https://www.reuters.com/sustainability/boards-policy-regulation/apple-loses-bid-pause-app-store-reform-order-epic-games-case-2025-06-04/</a>

AAPL

'Apple loses bid to pause app store reform order in Epic Games case'- Reuters

Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) has outperformed the market over the past 10 years by 5.64% on an annualized basis producing an average annual return of 16.72%. Currently, Marvell Tech has a market capitalization of $56.99 billion. 
Buying $100 In MRVL: If an investor had bought $100 of MRVL stock 10 years ago, it would be worth $477.32 today based on a price of $66.10 for MRVL at the time of writing.
<h3>Marvell Tech's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749071712_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MRVL

$100 Invested In Marvell Tech 10 Years Ago Would Be Worth This Much Today

Signet Jewelers Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) reported better-than-expected first-quarter financial results and <a href="https://www.benzinga.com/quote/SIG/earnings">raised its FY26 guidance on Tuesday.</a>
The company posted revenue of $1.54 billion, a 2% increase from the prior year, surpassing analysts&#8217; consensus estimate of $1.49 billion. Adjusted EPS of $1.18 beat the consensus estimate of $1.07.
"We delivered positive same-store sales growth each month of the quarter, and into May, by bolstering our offerings at key price points and continuing the evolution of our assortment. Our three largest brands – Kay, Zales, and Jared – all saw sequential comp sales improvement from the fourth quarter on higher margins, highlighting the impact of our outsized focus on our larger brands," stated J.K. Symancyk, Chief Executive Officer.
Signet raised its 2026 revenue guidance to a range of $6.57 billion to $6.80 billion, up from $6.53 billion to $6.80 billion, compared with the consensus estimate of $6.69 billion.
The company increased its adjusted EPS forecast to $7.70 to $9.38, up from $7.31 to $9.10, versus the consensus of $8.45. It expects adjusted EBITDA between $615 million and $695 million, slightly higher than the prior range of $605 million to $695 million.
For the second quarter, Signet projects revenue of $1.47 billion to $1.51 billion, above the $1.34 billion estimate, and adjusted EBITDA of $53 million to $73 million.
Signet Jewelers shares fell 1.1% to close at $74.40 on Wednesday.
These analysts made changes to their price targets on Signet following earnings announcement.
<ul class="wp-block-list">
<li>Telsey Advisory Group analyst Dana Telsey maintained Signet Jewelers with a Market Perform and raised the price target from $62 to $80.</li>
<li>B of A Securities analyst Lorraine Hutchinson maintained the stock with a Neutral and raised the price target from $65 to $78.</li>
<li>Wells Fargo analyst Ike Boruchow maintained Signet Jewelers with an Equal-Weight and raised the price target from $70 to $75.</li>
<li>UBS analyst Mauricio Serna maintained the stock with a Buy and raised the price target from $84 to $95.</li>
<li>Citigroup analyst Paul Lejuez maintained Signet Jewelers with a Buy and raised the price target from $85 to $100.</li>
</ul>
Considering buying SIG stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/SIG/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="548" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04171403/image-55-1024x548.png" alt="" class="wp-image-938834" style="width:598px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04171403/image-55-1024x548.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04171403/image-55-300x161.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04171403/image-55-768x411.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04171403/image-55.png 1052w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/06/45762621/cramer-shouldve-told-investors-to-pull-the-trigger-on-trade-desk-cant-believe-how-low-gentex-has-fal">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a></li>
</ul>

Price Target

These Analysts Increase Their Forecasts On Signet Jewelers After Better-Than-Expected Q1 Earnings

EBTC

INDB

Independent Bank And Enterprise Bancorp Receive All Required Regulatory Approvals Relating To The Proposed Transaction; The Proposed Transaction Is Expected To Be Completed On July 1, 2025

DVAX

Dynavax Technologies Comments On A Report Published By Glass, Lewis & Co; Says Is Already Delivering Significant Long-Term Stockholder Value Through Execution Of Current Strategy Overseen By Board; Deep Track's Inferior Short-Term Plan And Nominees Are Not In The Best Interests Of All Stockholders

<h3>Gainers</h3>
<ul>
<li>CTRL Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCTR#NASDAQ">MCTR</a>) stock rose 29.6% to $19.96 during Wednesday's after-market session. The company's market cap stands at $305.3 million. </li>
<li>Antelope Ent Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHL#NASDAQ">AEHL</a>) shares increased by 11.55% to $2.22. The market value of their outstanding shares is at $7.5 million. </li>
<li>iQSTEL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IQST#NASDAQ">IQST</a>) shares moved upwards by 6.49% to $12.29. The company's market cap stands at $35.6 million. </li>
<li>Dolphin Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLPN#NASDAQ">DLPN</a>) shares moved upwards by 5.62% to $1.2. The company's market cap stands at $13.3 million. </li>
<li>Token Cat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TC#NASDAQ">TC</a>) stock moved upwards by 5.59% to $0.82. The market value of their outstanding shares is at $2.5 million. </li>
<li>Baosheng Media Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAOS#NASDAQ">BAOS</a>) stock rose 4.91% to $3.84. The market value of their outstanding shares is at $5.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Kuke Music Hldg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KUKE#NYSE">KUKE</a>) stock declined by 6.9% to $2.85 during Wednesday's after-market session. The company's market cap stands at $20.4 million. </li>
<li>LQR House (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YHC#NASDAQ">YHC</a>) stock fell 6.25% to $1.35. The market value of their outstanding shares is at $1.4 million. </li>
<li>Blue Hat Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHAT#NASDAQ">BHAT</a>) shares declined by 5.27% to $1.8. The company's market cap stands at $8.8 million. </li>
<li>TNL Mediagene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNMG#NASDAQ">TNMG</a>) shares fell 4.99% to $0.56. The market value of their outstanding shares is at $15.8 million. </li>
<li>Global Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GITS#NASDAQ">GITS</a>) shares declined by 4.89% to $2.14. The company's market cap stands at $5.6 million. </li>
<li>QMMM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMMM#NASDAQ">QMMM</a>) stock fell 3.64% to $1.06. The company's market cap stands at $18.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEHL

BAOS

BHAT

DLPN

GITS

IQST

KUKE

MCTR

QMMM

TNMG

12 Communication Services Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) stock moved upwards by 89.2% to $24.05 during Wednesday's after-market session. The market value of their outstanding shares is at $642.4 million. </li>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) shares moved upwards by 27.84% to $0.73. The market value of their outstanding shares is at $5.2 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares increased by 12.55% to $4.8. The market value of their outstanding shares is at $73.0 million. </li>
<li>Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) stock increased by 10.43% to $0.51. The market value of their outstanding shares is at $23.4 million. </li>
<li>Meihua Intl Medical Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MHUA#NASDAQ">MHUA</a>) stock rose 7.09% to $0.6. The company's market cap stands at $15.3 million. </li>
<li>Femasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEMY#NASDAQ">FEMY</a>) stock rose 5.56% to $0.84. The market value of their outstanding shares is at $22.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) stock fell 17.4% to $1.95 during Wednesday's after-market session. The company's market cap stands at $63.7 million. </li>
<li>Bicara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAX#NASDAQ">BCAX</a>) stock decreased by 15.86% to $9.37. The market value of their outstanding shares is at $511.2 million. </li>
<li>Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) shares fell 12.31% to $0.28. The company's market cap stands at $10.9 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) shares decreased by 7.82% to $0.48. The market value of their outstanding shares is at $8.0 million. </li>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares declined by 6.48% to $1.59. The company's market cap stands at $27.8 million. </li>
<li>Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) stock declined by 6.33% to $10.73. The market value of their outstanding shares is at $1.3 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCAX

BOLT

CBUS

CLRB

FEMY

IMNN

KAPA

LIMN

MESO

MHUA

SILO

12 Health Care Stocks Moving In Wednesday's After-Market Session

Press Releases

Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results

Larimar Therapeutics to Participate in Upcoming Investor Conferences

Health Care

Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research

Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024

Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia

Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia

Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference

Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Comments

Larimar Therapeutics

Notizie

Ultime notizie per Larimar Therapeutics (NASDAQ:LRMR) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO